Skip to main content
Clinical Trials/NCT02046967
NCT02046967
Completed
Not Applicable

Comparative Randomized Clinical Trial of Steam Ablation Versus Endovenous Laser Ablation for the Treatment of Great Saphenous Veins

Erasmus Medical Center1 site in 1 country237 target enrollmentNovember 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Varicose Veins
Sponsor
Erasmus Medical Center
Enrollment
237
Locations
1
Primary Endpoint
Obliteration of varicose vein and/ or absence of reflux (>0.5 sec. of retrograde flow over >10cm) along the treated segment of the great saphenous vein (GSV) at 12 and 52 weeks.
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Endovenous laser ablation is a common therapy of great saphenous vein insufficiency with a very high success rate. It works by heating and thereby obliterating the vein. Steam ablation is a new therapy that also works by heating and thereby obliterating the vein. The hypothesis of this study is that steam ablation is as effective as laser ablation, but that it results in better secondary outcomes (e.g., lower pain scores).

Detailed Description

The study is a randomized clinical trial comparing two different therapies for endovenous ablation of great saphenous veins. The aim of the study is to test whether the anatomical success rate of Steam Ablation is not inferior to that of Endovenous laser ablation (EVLA) in treatment of great saphenous vein insufficiency and compare the treatment safety, patient reported outcomes and cost-effectiveness analyses between EVLA and Steam Ablation.

Registry
clinicaltrials.gov
Start Date
November 2009
End Date
March 2013
Last Updated
12 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

RR van den Bos

MD, PhD

Erasmus Medical Center

Eligibility Criteria

Inclusion Criteria

  • Patients over 18 years old
  • Insufficiency of the GSV measured with ultrasound imaging, reflux \> 0.5 s, and diameter of vein \> 0.5 cm
  • Symptoms of chronic venous insufficiency
  • No prior treatment of the insufficient GSV
  • Informed consent

Exclusion Criteria

  • Acute deep or superficial vein thrombosis
  • Agenesis of deep vein system
  • Vascular malformation or syndrome
  • Post-thrombotic syndrome, occlusive type
  • Pregnancy
  • Immobility
  • Allergy to lidocaine
  • Arterial insufficiency

Outcomes

Primary Outcomes

Obliteration of varicose vein and/ or absence of reflux (>0.5 sec. of retrograde flow over >10cm) along the treated segment of the great saphenous vein (GSV) at 12 and 52 weeks.

Time Frame: 52 weeks

Secondary Outcomes

  • Major complications: deep and superficial venous thrombosis (embolic events), nerve injury, skin burns, and (sub)cutaneous infections.(12 weeks)
  • Minor complications: ecchymosis, pain and hyperpigmentation.(12 weeks)
  • Health related quality of life will be measured using the Dutch Translated Aberdeen Varicose Vein Questionnaire (AVVQ).(12 weeks)
  • Treatment satisfaction(2 weeks)
  • Pain score(2 weeks)
  • Venous Clinical Severity Score (VCSS)(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials